Combined with the aforementioned research results, it can be speculated that in vivo treatment with STING agonists in tumor patients or mice may induce the activation of the STING pathway both in tumor cells and Tregs and avoid excessive activation of Tregs. This evidence concerns the gene STING1 and neoplasm.